{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:32:36Z","timestamp":1781602356683,"version":"3.54.5"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI11\/02081 and PI 11\/2345"],"award-info":[{"award-number":["PI11\/02081 and PI 11\/2345"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017 SGR 1342 and 2017 SGR 0742"],"award-info":[{"award-number":["2017 SGR 1342 and 2017 SGR 0742"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The lack of invasive pneumococcal disease (IPD) cost studies may underestimate the effect ofpneumococcal polysaccharide conjugated vaccines (PCV). The objective of this study was to estimatethe direct costs of hospitalized IPD cases. A prospective study was made in children aged &lt;5 yearsdiagnosed with IPD in two high-tech hospitals in Catalonia (Spain) between 2007\u20132009 (PCV7 period)and 2012\u20132015 (PCV13 period). Costs were calculated according to 2014 Catalan Health Service ratesusing diagnostic-related groups. In total, 319 and 154 cases were collected, respectively. Pneumoniahad the highest cost (65.7% and 62.0%, respectively), followed by meningitis (25.8% and 26.1%,respectively). During 2007\u20132015, the costs associated with PCV7 serotypes (Pearson coefficient (Pc) =\u22120.79; p = 0.036) and additional PCV13 serotypes (Pc = \u22120.75; p = 0.05) decreased, but those of otherserotypes did not (Pc = 0.23 p = 0.62). The total mean cost of IPD increased in the PCV13 period by31.4% (\u20ac3016.1 vs. \u20ac3963.9), mainly due to ICU stay (77.4%; \u20ac1051.4 vs. \u20ac1865.6). During the PCV13period, direct IPD costs decreased due to a reduction in the number of cases, but cases were more severe and had a higher mean cost. During 2015, IPD costs increased due to an increase in the costsassociated with non-PCV13 serotypes and serotype 3 and this requires further investigation.<\/jats:p>","DOI":"10.3390\/vaccines8030387","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:35:18Z","timestamp":1594809318000},"page":"387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of the 13-Valent Conjugated Pneumococcal Vaccine on the Direct Costs of Invasive Pneumococcal Disease Requiring Hospital Admission in Children Aged &lt; 5 Years: A Prospective Study"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-6190","authenticated-orcid":false,"given":"Sergi","family":"Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Public Health Agency of Catalonia, Generalitat de Catalunya, 08005 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna","family":"Navas","sequence":"additional","affiliation":[{"name":"Public Health Agency of Catalonia, Generalitat de Catalunya, 08005 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5968","authenticated-orcid":false,"given":"Ignacio","family":"Aznar-Lou","sequence":"additional","affiliation":[{"name":"Teaching, Research &amp; Innovation Unit, Institut de Recerca Sant Joan de D\u00e9u, Sant Boi de Llobregat, 08830 Barcelona, Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0842-7220","authenticated-orcid":false,"given":"Pilar","family":"Ciruela","sequence":"additional","affiliation":[{"name":"Public Health Agency of Catalonia, Generalitat de Catalunya, 08005 Barcelona, Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Hospital Sant Joan de D\u00e9u Barcelona, Universitat de Barcelona, Esplugues de Llobregat, 08950 Barcelona, Spain"},{"name":"Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de D\u00e9u, Esplugues de Llobregat, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Moraga-Llop","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5586-404X","authenticated-orcid":false,"given":"Carmen","family":"Mu\u00f1oz-Almagro","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Hospital Sant Joan de D\u00e9u Barcelona, Universitat de Barcelona, Esplugues de Llobregat, 08950 Barcelona, Spain"},{"name":"Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de D\u00e9u, Esplugues de Llobregat, 08950 Barcelona, Spain"},{"name":"Departament de Medicina, Universitat Internacional de Catalunya, 08017 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Codina","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"F. de Sevilla","sequence":"additional","affiliation":[{"name":"Hospital Sant Joan de D\u00e9u Barcelona, Universitat de Barcelona, Esplugues de Llobregat, 08950 Barcelona, Spain"},{"name":"Malalties Prevenibles amb Vacunes, Institut de Recerca Sant Joan de D\u00e9u, Esplugues de Llobregat, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e0","family":"Gonz\u00e1lez-Peris","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Esteva","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Hospital Sant Joan de D\u00e9u Barcelona, Universitat de Barcelona, Esplugues de Llobregat, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Planes","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conchita","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Public Health Agency of Catalonia, Generalitat de Catalunya, 08005 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mart\u00ednez-Osorio","sequence":"additional","affiliation":[{"name":"Hospital Sant Joan de D\u00e9u Barcelona, Universitat de Barcelona, Esplugues de Llobregat, 08950 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Campins","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Epidemiology and Public Health Research Group, Vall d\u2019Hebron Institut de Recerca, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Uriona","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Epidemiology and Public Health Research Group, Vall d\u2019Hebron Institut de Recerca, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Salleras","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Departament de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6123-0633","authenticated-orcid":false,"given":"Antoni","family":"Serrano-Blanco","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Parc Sanitari Sant Joan de D\u00e9u, Sant Boi de Llobregat, 08830 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-6723","authenticated-orcid":false,"given":"Mireia","family":"Jan\u00e9","sequence":"additional","affiliation":[{"name":"Public Health Agency of Catalonia, Generalitat de Catalunya, 08005 Barcelona, Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-1907","authenticated-orcid":false,"given":"\u00c1ngela","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Departament de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, K.L., Wolfson, L.J., Watt, J.P., Henkle, E., Deloria Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O.S., and Cherian, T. (2009). Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: Global estimates. Lancet, 893\u2013902.","DOI":"10.1016\/S0140-6736(09)61204-6"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: Global, regional, and national estimates for 2000\u201315","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_3","unstructured":"World Health Organization (2019). Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper\u2014February 2019. Wkly. Epidemiol. Rec., 94, 85\u2013104."},{"key":"ref_4","unstructured":"(2020, July 06). Summary of Prevenar 7 Product Characteristics. European Medicines Agency. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000323\/WC500041558.pdf."},{"key":"ref_5","unstructured":"(2020, July 06). Summary of Synflorix Product Characteristics. European Medicines Agency. Available online: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Pro-duct_Information\/human\/000973\/WC500054346.pdf."},{"key":"ref_6","unstructured":"(2020, July 06). Summary of Prevenar 13 Product Characteristics. European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/prevenar-epar-summary-public_en.pdf."},{"key":"ref_7","unstructured":"European Centre for Disease Prevention and Control (2019). Invasive Pneumococcal Disease, ECDC. Available online: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/AER_for_2017-invasive-pneumococcal-disease.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: An active prospective nationwide surveillance","volume":"32","author":"Greenberg","year":"2014","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Fortunato, F., Martinelli, D., Cappelli, M.G., Cozza, V., and Prato, R. (2015). Impact of pneumococcal conjugate universal routine vaccination on pneumococcal disease in Italian children. J. Immunol. Res.","DOI":"10.1155\/2015\/206757"},{"key":"ref_10","first-page":"995","article-title":"Declines in pneumonia hospitalizations of children aged <2 years associated with the use of pneumococcal conjugate vaccines\u2014Tennessee, 1998\u20132012","volume":"63","author":"Griffin","year":"2014","journal-title":"MWR Morb. Mortal. Wkly Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.vaccine.2014.11.011","article-title":"Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012","volume":"33","author":"Lepoutre","year":"2015","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.vaccine.2014.03.054","article-title":"Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013","volume":"32","author":"Guevara","year":"2014","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: Analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1128\/CVI.00239-13","article-title":"Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain","volume":"20","author":"Picazo","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/INF.0b013e31827e8594","article-title":"Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011","volume":"32","author":"Picazo","year":"2013","journal-title":"Pediatr. Infect Dis. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40273-013-0113-y","article-title":"Cost effectiveness of the new pneumococcal vaccines: A systematic review of European studies","volume":"32","author":"Duranti","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"010408","DOI":"10.7189\/jogh.06.010408","article-title":"Cost of management of severe pneumonia in young children: Systematic analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"J. Glob. Health"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.vaccine.2012.12.025","article-title":"Cost of hospitalizing children with invasive pneumococcal pneumonia","volume":"31","author":"Brotons","year":"2013","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Baldo, V., Cocchio, S., Baldovin, T., Buja, A., Furlan, P., Bertoncello, C., Russo, F., and Saia, M. (2014). A population-based study on the impact of hospitalization for pneumonia in different age groups. BMC Infect Dis., 14.","DOI":"10.1186\/1471-2334-14-485"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Spoorenberg, S.M., Bos, W.J., Heijligenberg, R., Voorn, P.G., Grutters, J.C., Rijkers, G.T., and van de Garde, E.M. (2014). Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-335"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Song, J.Y., Choi, J.Y., Lee, J.S., Bae, I.G., Kim, Y.K., Sohn, J.W., Jo, Y.M., Choi, W.S., Lee, J., and Park, K.H. (2013). Clinical and economic burden of invasive pneumococcal disease in adults: A multicenter hospital-based study. BMC Infect Dis., 13.","DOI":"10.1186\/1471-2334-13-202"},{"key":"ref_23","first-page":"92","article-title":"Economic cost of Streptococcus pneumoniae community-acquired pneumonia, meningitis and bacteremia in an adult population that required hospitalization in Bogot\u00e1, Colombia","volume":"34","author":"Dennis","year":"2014","journal-title":"Biomedica"},{"key":"ref_24","unstructured":"Registre del Conjunt M\u00ednim B\u00e0sic de Dades (CMBD) dels Hospital D\u2019aguts (2020, July 06). Servei Catal\u00e0 de la Salut. Available online: http:\/\/catsalut.gencat.cat\/ca\/proveidors-professionals\/registres-catalegs\/registres\/cmbd\/informes-anuals\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1469-0691.2008.02028.x","article-title":"Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR","volume":"14","author":"Fenoll","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","unstructured":"World Health Organization (2019). Neisseria Meningitidis, Streptococcus Pneumoniae, Diagnosis of Meningitis Caused by Laboratory Methods for the and Haemophilus Influenzae: WHO Manual, World Health Organization. [2nd ed.]. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/70765\/WHO_IVB_11.09_eng.pdf?sequence=1."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/jcm.35.3.764-766.1997","article-title":"Dot blot assay for the serotyping of pneumococci","volume":"35","author":"Fenoll","year":"1997","journal-title":"J. Clin. Microbiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1128\/JCM.00906-14","article-title":"Direct identification of Streptococcus pneumoniae capsular types in pleural fluids by using multiplex PCR combined with automated fluorescence-based capillary electrophoresis","volume":"52","author":"Selva","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","unstructured":"(2020, July 06). DECRET 170\/2010, de 16 de Novembre, de Regulaci\u00f3 del Sistema de Pagament dels Convenis i Contractes de Gesti\u00f3 de Serveis Assistencials en l\u2019\u00e0mbit del Servei Catal\u00e0 de la Salut. Available online: https:\/\/portaljuridic.gencat.cat\/eli\/es-ct\/d\/2010\/11\/16\/170."},{"key":"ref_30","unstructured":"(2020, July 06). ORDRE SLT\/79\/2014, de 12 de Mar\u00e7, per la Qual es Determinen per a L\u2019any 2014 els Preus Unitaris i la Resta de Valors a Qu\u00e8 es Refereix L\u2019article 5 del Decret 170\/2010, de 16 de Novembre, de Regulaci\u00f3 del Sistema de Pagament de Serveis Sanitaris en L\u2019\u00e0mbit del Servei Catal\u00e0 de la Salut. Available online: https:\/\/portaljuridic.gencat.cat\/eli\/es-ct\/o\/2014\/03\/12\/slt79."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Navas, E., Torner, N., Broner, S., Godoy, P., Mart\u00ednez, A., Bartolom\u00e9, R., Dom\u00ednguez, A., and Working Group for the Study of Outbreaks of Acute Gastroenteritis in Catalonia (Spain) (2015). Economic costs of outbreaks of acute viral gastroenteritis due to norovirus in Catalonia (Spain), 2010\u20132011. BMC Public Health, 15.","DOI":"10.1186\/s12889-015-2289-x"},{"key":"ref_32","unstructured":"(2020, July 06). Ordre SLT\/99\/2013, de 24 de Maig, per la Qual S\u2019estableixen per a L\u2019any 2013 les Tarifes M\u00e0ximes dels Serveis de Transport Sanitari no Urgent que Convingui o Contracti el Servei Catal\u00e0 de la Salut. Available online: https:\/\/portaljuridic.gencat.cat\/eli\/es-ct\/o\/2013\/05\/24\/slt99."},{"key":"ref_33","unstructured":"(2020, July 06). ORDRE SLT\/78\/2014, de 12 de Mar\u00e7, per la qual es Prorroguen per a L\u2019any 2014 les Tarifes M\u00e0ximes Corresponents a la Prestaci\u00f3 i Concertaci\u00f3 de Determinats Serveis Sanitaris. Available online: https:\/\/portaljuridic.gencat.cat\/eli\/es-ct\/o\/2014\/03\/12\/slt78."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/21645515.2017.1371378","article-title":"Economic burden of pneumococcal infections in children under 5 years of age","volume":"14","author":"Ceyhan","year":"2018","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00363-19","DOI":"10.1128\/JCM.00363-19","article-title":"Invasive pneumococcal disease and influenza activity in a pediatric population: Impact of PCV13 vaccination in pandemic and nonpandemic influenza periods","volume":"57","author":"Ciruela","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1590\/S1020-49892009000800002","article-title":"Direct medical costs of invasive pneumococcal disease and radiologically-diagnosed pneumonia among Chilean children","volume":"26","author":"Lagos","year":"2009","journal-title":"Rev. Panam Salud P\u00fablica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/INF.0000000000001709","article-title":"Changes in the nature and severity of invasive pneumococcal disease in children before and after the seven-valent and thirteen-valent pneumococcal conjugate vaccine programs in Calgary, Canada","volume":"37","author":"Ricketson","year":"2018","journal-title":"Pediatr. Infect Dis. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1016\/j.vaccine.2018.05.026","article-title":"The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage","volume":"36","author":"Ciruela","year":"2018","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1086\/524660","article-title":"Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine","volume":"46","author":"Jordan","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Feikin, D.R., Kagucia, E.W., Loo, J.D., Link-Gelles, R., Puhan, M.A., Cherian, T., Levine, O.S., Whitney, C.G., O\u2019Brien, K.L., and Moore, M.R. (2013). Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med., 10.","DOI":"10.1371\/journal.pmed.1001517"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.vaccine.2019.10.056","article-title":"Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion\/empyema after the introduction of PCV13 in Germany","volume":"38","author":"Goettler","year":"2020","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez, \u00c1., Ciruela, P., Hern\u00e1ndez, S., Garc\u00eda-Garc\u00eda, J.J., Soldevila, N., Izquierdo, C., Moraga-Llop, F., D\u00edaz, A., F de Sevilla, M., and Gonz\u00e1lez-Peris, S. (2017). Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183191"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3201\/eid2606.190951","article-title":"Failures of 13-valent conjugated pneumococcal vaccine in age-appropriately vaccinated children 2\u201359 months of age, Spain","volume":"26","author":"Ciruela","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2213-2600(17)30110-8","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: An observational multicentre study","volume":"5","author":"Savulescu","year":"2017","journal-title":"Lancet Respir. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/387\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:44Z","timestamp":1760176124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/3\/387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["vaccines8030387"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8030387","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}